Form 4: Castle Biosciences CEO Derek Maetzold Executes Stock Transactions Under 10b5-1 Plan
SEC Form 4 Filing
Castle Biosciences CEO Derek J. Maetzold reported the acquisition and disposal of common stock and restricted stock units, executed under a pre-arranged 10b5-1 trading plan.
Summary
- On March 4, 2025, Derek J. Maetzold, the President and CEO of Castle Biosciences, executed several transactions involving the company's common stock and restricted stock units (RSUs).
- These transactions included the acquisition of 31,109 shares through the vesting of RSUs and the disposal of shares to cover tax obligations and sales under a pre-arranged Rule 10b5-1 trading plan.
- The sales were executed at a weighted-average price of $20.858 per share.
- Following these transactions, Maetzold directly owns 103,104 shares of common stock.
- Maetzold also has indirect ownership through various trusts, including The Maetzold Descendants 2020 Trust (69,059 shares), Derek Maetzold 2020 Irrevocable Trust (58,834 shares), and several remainder trusts for his children (4,938 or 4,935 shares each).
- Additionally, Maetzold holds shares through DJM Grantor Retained Annuity Trusts No. 5 (122,866 shares) and No. 6 (26,134 shares).
- Maetzold directly owns 93,328 RSUs after the transactions.
- The RSUs vest in four equal annual installments beginning on March 4, 2026.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing simply reports transactions by an insider under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Future Outlook
The transactions were conducted under a pre-arranged 10b5-1 trading plan, suggesting continued, scheduled transactions in the future.
Industry Context
Form 4 filings are routine disclosures for corporate insiders and are closely watched by investors for insights into management's perspective on the company's stock.
Key Dates
| Date | Description |
|---|---|
| 11/11/2024 | Date of adoption of Rule 10b5-1 plan by the Reporting Person, The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, The Maetzold 2018 Remainder Trust f/b/o Emily Carol Kirk, The Maetzold 2018 Remainder Trust f/b/o Hannah Elizabeth Maetzold, The Maetzold 2018 Remainder Trust f/b/o John Derek Maetzold, and The Maetzold 2018 Remainder Trust f/b/o Peter Douglas Maetzold. |
| 03/04/2025 | Date of transactions involving common stock and restricted stock units. |
| 03/04/2026 | First vesting date for the newly granted RSUs. |
Keywords
Form 4, insider trading, stock sale, restricted stock units, Rule 10b5-1, CSTL, Castle Biosciences, Maetzold, CEO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.